adjuvant

(redirected from Adjuvant therapy)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Adjuvant therapy: Adjuvant chemotherapy

adjuvant

[′aj·ə·vənt]
(pharmacology)
A material that enhances the action of a drug or antigen.
References in periodicals archive ?
lower abdomen), adjacent organ resection (yes or no), adjuvant therapy (yes or no), ascites (yes or no), and postoperative metastasis (yes or no).
Studies examining the influence of relative dose intensity (RDI) of adjuvant therapy on RFS in patients with colon cancer treated with 5FU/LV showed no effect of increased duration of therapy on recurrence-free survival (RFS) [17,18].
In our study, a 5-year survival of 60% for the adjuvant therapy group was significantly higher than the group that received neoadjuvant therapy and was also higher than the group that received surgery alone, 33% and 30%, respectively.
All patients underwent surgical treatment with or without adjuvant therapy. Type I hysterectomy was performed in 24 patients (88.8%) and type III hysterectomy in three patients (11.1%).
Twenty-nine (83%) patients were treated with a combination of systemic corticosteroids and adjuvant therapy (defined as one or more of the following: mycophenolate mofetil, azathioprine, dapsone, tetracyclines, methotrexate, rituximab, and intravenous immunoglobulin).
(4) A five-year course of tamoxifen adjuvant therapy after surgery significantly decreases disease recurrence rates and reduces breast cancer mortality for both pre-and postmenopausal women with ER-positive tumors.
The identification of risk factors for extraocular relapse is critical for determining indications for adjuvant therapy. Traditionally, the decision to prescribe adjuvant therapy after enucleation has depended on presence of PRFs.
An aromatase inhibitor should be considered as adjuvant therapy for all postmenopausal women with hormone receptor-positive breast cancer, according to an updated American Society of Clinical Oncology clinical practice guideline.
Eng advised the decedent that the decedent would not require adjuvant therapy. In August, September, and October 2002, the decedent continued to see Dr.
Cohorts 2 and 3 consisted of 214 patients drawn from prospective randomized, controlled trials of adjuvant therapy with interferon alfa.
In contrast, there were 83 recurrences among 2,157 postmenopausal women who got extended adjuvant therapy with letrozole, for an absolute 3.3% improvement over placebo in terms of 4-year disease-free survival (HR = 0.69,P = .0008).
Because hydrocortisone therapy did not lead to better outcomes in patients with septic shock, it is not recommended that it be used as general adjuvant therapy for this condition.